Inactive disease under treatment at last follow-up
| First agent (%) | Second agent (%) | Third agent (%) | Fourth agent (%) | |
|---|---|---|---|---|
| Etanercept | 1/12 (8) | 0/4 (0) | – | 0/1 (0) |
| Adalimumab | 0/1 (0) | 0/2 (0) | 0/1 (0) | – |
| Abatacept | 1/1 (100) | 0/1 (0) | 0/1 (0) | – |
| Anakinra | 26/51 (51) | 0/7 (0) | 0/1 (0) | – |
| Canakinumab | 7/10 (70) | 4/14 (29) | 2/5 (40) | 0/2 (0) |
| Tocilizumab | 2/2 (100) | 2/6 (33) | 4/11 (36) | 1/1 (100) |
| Total inactive disease | 37/77 | 6/34 | 6/19 | 1/4 |